Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Freeline Therapeutics Holdings plc (FRLN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.8963+0.0186 (+2.12%)
At close: 04:00PM EDT
0.8800 -0.02 (-1.82%)
After hours: 06:29PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.8777
Open0.8787
Bid0.8800 x 1800
Ask0.9100 x 3200
Day's Range0.8310 - 0.9196
52 Week Range0.6500 - 15.4000
Volume53,863
Avg. Volume123,395
Market Cap58.015M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.5290
Earnings DateMay 10, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for FRLN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Freeline Therapeutics Holdings
    Daily – Vickers Top Buyers & Sellers for 05/19/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • GlobeNewswire

    Freeline Announces June 2022 Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    LONDON, July 01, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on June 30, 2022, the Company granted a newly hired employee non-statutory options to purchase 5,500 of the Company’s ordinary shares. The award was granted as an inducement material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and was approved by an independent subcommittee of the remuneration committee of Freeline’s boar

  • GlobeNewswire

    Freeline to Present New Clinical Data for FLT180a in Hemophilia B at International Society on Thrombosis and Haemostasis Congress

    LONDON, June 24, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the upcoming presentation of new and important clinical data for its AAVS3-based gene therapy candidate FLT180a at the International Society on Thrombosis and Haemostasis (ISTH) Congress to be held in London, July 9-13, 2022. The presentation will provide safety and initial efficacy data from the first cohort of the Phase 1/2 B-LIEVE trial, which aims to confirm the FLT180a dose and immune

  • GlobeNewswire

    Freeline Initiates Dosing of Second Cohort in B-LIEVE Dose Confirmation Trial of FLT180a in Hemophilia B

    Initial cohort one data suggest predictable and sustained Factor IX normalization, supporting additional dosing at the same low dose with the same optimized, prophylactic immune management regimen Cohort one efficacy and safety data to be presented at ISTH Congress in July Start-up activities for pivotal Phase 3 trial on track to begin in H1 2023 LONDON, June 14, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it has begun dosing the second cohort

Advertisement
Advertisement